ReadeRx Therapeutics

RNA-based Cancer Therapeutics

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in January 2023, ReadeRx Therapeutics operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing novel cancer treatments.

Business overview

ReadeRx Therapeutics is a Health Tech & Life Sciences company specializing in RNA-based cancer therapeutics. The company develops small molecule inhibitors that target the RNA binding protein IGF2BP1, which plays a pivotal role in stabilizing pro-oncogenic RNAs in various cancer types. By inhibiting IGF2BP1, ReadeRx aims to offer a novel treatment strategy for cancer, serving the pharmaceutical and healthcare industries.

Log in to access full profile

Company Intelligence Q&A

What is ReadeRx Therapeutics' primary focus?
ReadeRx Therapeutics is focused on developing RNA-based cancer therapeutics, specifically small molecule inhibitors targeting the RNA binding protein IGF2BP1.
When was ReadeRx Therapeutics founded?
ReadeRx Therapeutics was founded in January 2023.
What is the core technology behind ReadeRx Therapeutics' approach?
The core technology involves developing small molecule inhibitors to target the RNA binding protein IGF2BP1, which is reactivated in many cancers and promotes pro-oncogenic processes.
What problem does IGF2BP1 inhibition address in cancer therapy?
IGF2BP1 is an oncofetal RNA binding protein that stabilizes key pro-oncogenic RNAs in many cancers. Its inhibition is considered a promising strategy for cancer therapy by disrupting these pro-tumorigenic processes.
What is the current stage of ReadeRx Therapeutics' product development?
ReadeRx Therapeutics is currently in the R&D stage for its products, focusing on developing small molecule inhibitors for cancer treatment.
Log in to access full profile